» Articles » PMID: 28176023

Postoperative Weight Loss Leads to Poor Survival Through Poor S-1 Efficacy in Patients with Stage II/III Gastric Cancer

Overview
Specialty Oncology
Date 2017 Feb 9
PMID 28176023
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: We previously demonstrated that body weight loss (BWL) at one month after gastrectomy, a common finding after surgery for gastric cancer, was an independent risk factor for the continuation of adjuvant chemotherapy with S-1. However, it is unclear whether BWL after gastrectomy leads to poor survival through poor compliance to adjuvant chemotherapy with S-1.

Methods: We conducted this follow-up study in the same cohort as our previous study. Overall survival (OS) and recurrence-free survival (RFS) were examined in 103 patients who underwent curative D2 surgery and were pathologically diagnosed with stage II or III gastric cancer, and who received postoperative adjuvant chemotherapy with S-1 between June 2002 and December 2011.

Results: The median follow-up period was 64.3 months. The 5-year OS rate in the patients with a BWL of <15% was 59.9%, while that in the patients with a BWL of ≥15% was 36.4% (p = 0.004). Univariate and multivariate analyses for OS demonstrated that pathological T factor and BWL were significant risk factors. On the other hand, the 5-year RFS rate was 56.4% in the BWL <15% group and 36.4% in the BWL ≥15% group (p = 0.016), while univariate and multivariate analyses for RFS demonstrated that BWL was a marginally significant risk factor.

Conclusions: Severe postoperative BWL, which is closely related with poor S-1 compliance, is an important risk factor for survival. It merits testing if preventing BWL improves survival of gastric cancer patients who receive S-1 adjuvant chemotherapy.

Citing Articles

Efficacy and safety of post-discharge oral nutritional supplements for patients with gastric cancer undergoing gastrectomy: a meta-analysis of randomized controlled trials.

Liang Q, Wang S, Wang B, Hong Y Front Nutr. 2025; 11:1488054.

PMID: 39877540 PMC: 11772097. DOI: 10.3389/fnut.2024.1488054.


Preoperative low prealbumin independently predicts non-gastric cancer death after gastrectomy in elderly and young patients: a retrospective cohort study.

Matsui R, Nunobe S, Ri M, Makuuchi R, Irino T, Hayami M Surg Today. 2025; .

PMID: 39870988 DOI: 10.1007/s00595-025-02996-1.


Predictors of tolerability for postoperative adjuvant S1 plus docetaxel chemotherapy for gastric cancer: a multicenter retrospective study.

Toyota K, Tanabe K, Kano M, Komo T, Hotta R, Yanagawa S Gastric Cancer. 2024; 28(1):102-111.

PMID: 39520590 PMC: 11706876. DOI: 10.1007/s10120-024-01563-w.


Clinical Impact of Weight Loss During Hospitalization on Prognosis After Pancreatic Surgery.

Kuwabara S, Nakaya T, Ishido K, Aoki Y, Yamamoto K, Shoji Y Cureus. 2024; 16(9):e69427.

PMID: 39411627 PMC: 11473965. DOI: 10.7759/cureus.69427.


Comparison of the influence of postoperative oral nutritional supplementation between octogenarian and non-octogenarian patients undergoing gastrectomy for cancer.

Maruyama S, Kawaguchi Y, Akaike H, Shoda K, Higuchi Y, Nakayama T World J Surg Oncol. 2024; 22(1):267.

PMID: 39379978 PMC: 11459882. DOI: 10.1186/s12957-024-03549-5.


References
1.
Andreyev H, Norman A, Oates J, Cunningham D . Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?. Eur J Cancer. 1998; 34(4):503-9. DOI: 10.1016/s0959-8049(97)10090-9. View

2.
. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011; 14(2):113-23. DOI: 10.1007/s10120-011-0042-4. View

3.
Aoyama T, Yoshikawa T, Shirai J, Hayashi T, Yamada T, Tsuchida K . Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. Ann Surg Oncol. 2012; 20(6):2000-6. DOI: 10.1245/s10434-012-2776-6. View

4.
Yamada T, Hayashi T, Cho H, Yoshikawa T, Taniguchi H, Fukushima R . Usefulness of enhanced recovery after surgery protocol as compared with conventional perioperative care in gastric surgery. Gastric Cancer. 2011; 15(1):34-41. DOI: 10.1007/s10120-011-0057-x. View

5.
Ryan A, Reynolds J, Healy L, Byrne M, Moore J, Brannelly N . Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial. Ann Surg. 2009; 249(3):355-63. DOI: 10.1097/SLA.0b013e31819a4789. View